Expensive cancer drugs with modest benefit ignite debate over solutions.
Sinha
Gunjan
G
D000970:Antineoplastic Agents / Q000191:economics* / Q000627:therapeutic use*; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage / Q000009:adverse effects; D047072:Aromatase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects; D003362:Cost-Benefit Analysis; D018572:Disease-Free Survival; D016527:Drug Costs; D019317:Evidence-Based Medicine; D006801:Humans; D019458:Insurance Coverage; D017410:Practice Guidelines as Topic; D013629:Tamoxifen / Q000008:administration & dosage / Q000009:adverse effects; D016896:Treatment Outcome; D006113:United Kingdom; D014481:United States
D000970:Antineoplastic Agents; D018931:Antineoplastic Agents, Hormonal; D047072:Aromatase Inhibitors; D013629:Tamoxifen